BPC-157 and TB-500: what the FDA is actually reviewing
The July 23–24 advisory meeting decides whether these substances reach the 503A Bulks List. Here's the evidence the committee weighs — and what each outcome would actually change.
Last reviewed July 14, 2026 · Updated after every FDA action · Not legal or medical advice
What's actually being decided
The committee is not deciding whether BPC-157 and TB-500 work, and it is not deciding whether they're safe to sell. It's deciding one narrow question: do these substances belong on the 503A Bulks List — the list that lets a licensed pharmacy compound something that has no USP monograph and isn't part of an FDA-approved drug.
That's the only door available to these compounds, because neither meets the other two conditions. The committee's answer is a recommendation. The FDA isn't bound by it, and nothing reaches the list without a separate rulemaking process afterward.
Just want the current status? →
The three years behind a two-day meeting
How these peptides ended up in front of a committee
The review didn't come out of nowhere. It's the product of a restriction, a lawsuit, and a settlement.
The FDA placed nineteen peptide substances into Category 2 of its interim 503A policy, meaning compounding pharmacies could not legally use them. The list included BPC-157, TB-500, Thymosin Alpha-1, CJC-1295 and Ipamorelin. Regulated access ended effectively overnight.
Two compounding-sector companies, Evexias and Farmakeio, sued in federal court in Texas under the Administrative Procedure Act, arguing the FDA had acted without adequate process. The suit named AOD-9604, CJC-1295, Ipamorelin and Thymosin Alpha-1.
The FDA settled, agreeing to route peptides through formal advisory-committee review rather than maintaining Category 2 status unilaterally. That settlement is why a PCAC meeting exists at all.
The FDA removed BPC-157, TB-500 and others from Category 2 and published a Federal Register notice scheduling the review. Removal lifted a restriction. It did not grant permission, and it did not move anything to the list.
The committee meets. See the agenda →
The test
The four things the committee weighs
Every nominated substance is measured against the same four factors. They're worth knowing, because they explain why a compound with enthusiastic users can still fail the test.
Characterization
How well-established is the substance's physical and chemical identity? A committee can't assess a substance it can't precisely define — including whether the free base and acetate forms behave the same way. Each is reviewed separately for exactly this reason.
Safety
What's actually known about risk when the substance is used in compounding? This includes questions that don't come up in supplement debates — like immunogenicity, the chance the body mounts an immune response to an injected peptide.
Effectiveness
Is there evidence the substance works for the specific proposed use, by the specific proposed route? This is narrower than most people expect. Broad enthusiasm doesn't substitute for evidence tied to the indication under review.
Historical use in compounding
What's the track record — how long has it been compounded, for what condition, and what does the medical literature record about it?
Worth being direct about the evidence picture, because it doesn't change with the legal one: BPC-157's human data is a small handful of studies. TB-500 has no completed human randomized controlled trials. A recommendation either way wouldn't alter that. Legal status and clinical evidence are separate questions, and reclassification never validated efficacy.
Every possible ending
Three outcomes. Here's what each one actually changes.
| Question | Positive recommendation | Negative recommendation | More data requested |
|---|---|---|---|
| What the committee says | Recommends adding the substance to the 503A list | Recommends against adding it | Defers, asking for further safety or effectiveness evidence |
| What the FDA does next | Considers the recommendation. Must still run a formal rulemaking process — a proposed rule, a public comment period, then a final rule — before anything is added. | Considers the recommendation. The substance stays outside the compounding framework. | The review timeline extends. No change to the list. |
| Realistic timeline | Months, not days. Well beyond 2026 for compounded product to actually exist. | Indefinite. | Indefinite. |
| What you can get on July 25 | Nothing new. | Nothing new. | Nothing new. |
| What Peptos does | Education and waitlist continue. We market it when a licensed clinician can prescribe it through a compliant pharmacy — not before. | Education continues. We say so plainly and update the board. | Education continues. We update the board with the date. |
Every column ends in the same place
Read the bottom of that table again. Whatever the committee recommends, nothing you can order changes on July 25. A positive vote starts a rulemaking process; it doesn't finish one. A negative vote closes a door that was already closed.
That's the gap worth watching for. In the days after this meeting, a lot of sites will describe a recommendation as though it were permission — the same way "removed from Category 2" got sold as "cleared to buy" in April. The vote is a real milestone and we'll cover it. It is not a starting gun, and anyone telling you otherwise is telling you what they need you to believe.
Where these compounds stand today
Two signals, kept separate: the regulatory status, and what it means for you.
See the full tracker and the changelog →
Compounded, not FDA-approved. Compounded medications are prepared by a licensed pharmacy for an individual patient and are not reviewed by the FDA for safety, effectiveness, or manufacturing the way approved drugs are. They are not the same as brand-name products, and they're only appropriate when a licensed clinician determines FDA-approved options don't fit your situation.
You don't have to wait on a committee
If you came here for recovery, energy, longevity or weight, there are compounded therapies a licensed clinician can prescribe today where they're clinically appropriate — matched to your goal, your health history and your state. Two minutes tells you what you're eligible for. Nothing to pay to find out.
Questions people ask
What is the FDA reviewing for BPC-157 and TB-500?
One narrow question: whether each substance belongs on the Section 503A Bulk Drug Substances List — the list that lets a licensed pharmacy compound a substance that has no USP monograph and isn't a component of an FDA-approved drug. Neither compound meets those other two conditions, so the list is the only available pathway.
What are the four factors the committee considers?
How well the substance is physically and chemically characterized; what's known about its safety in compounding, including immunogenicity; whether there's evidence it's effective for the specific proposed use and route; and its history of use in compounding and in the medical literature.
What happens if the committee recommends adding them?
The FDA considers the recommendation but isn't bound by it. Adding a substance still requires a formal rulemaking process — a proposed rule, a public comment period, and a final rule. That takes months. A positive recommendation on July 23 would not make compounded BPC-157 available in 2026.
What happens if the committee recommends against?
The substance stays outside the compounding framework. The FDA makes the final determination, and a negative recommendation generally means it doesn't reach the list.
Does anything change on July 24?
No. Whatever the recommendation, nothing you can obtain changes when the meeting ends. A vote is not authorization. We'll post the outcome and update every status on the tracker, and we'll be specific about what it does and doesn't mean.
What can a clinician prescribe right now?
Depending on your health history and your state, a licensed clinician may prescribe compounded semaglutide or tirzepatide, sermorelin, NAD+ and B12, among others. These are compounded and not FDA-approved. The eligibility check shows what applies to you before anyone charges you anything.